These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37676725)

  • 1. Letermovir for pre-emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation.
    Kaur R; Purtill D; Cooney J; Cannell P; Wright M; Copeland TS; McGuire M; Boan P
    Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14147. PubMed ID: 37676725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.
    Rho E; Näf B; Müller TF; Wüthrich RP; Schachter T; von Moos S
    Clin Transplant; 2021 Nov; 35(11):e14401. PubMed ID: 34181768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction.
    Jorgenson MR; Descourouez JL; Saddler CM; Smith JA; Odorico JS; Rice JP; Mandelbrot DA
    Clin Transplant; 2023 Dec; 37(12):e15142. PubMed ID: 37755141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation.
    Tan CA; Palen L; Su Y; Li Y; Gennarelli RL; Perales MA; Cohen N; Papanicolaou GA; Shah GL; Seo SK
    Transplant Cell Ther; 2024 Aug; 30(8):792.e1-792.e12. PubMed ID: 38838781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial.
    Liu KY; Wang Y; Han MZ; Huang H; Chen H; Liu QF; Wang JM; Liu T; Song YP; Ma J; Wu DP; Zou P; Huang XJ
    Chin Med J (Engl); 2010 Aug; 123(16):2199-205. PubMed ID: 20819665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
    Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
    Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letermovir for Cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation.
    Chen TT; David AP; Barthelmess EK; MacBrayne CE
    Pediatr Blood Cancer; 2023 Nov; 70(11):e30608. PubMed ID: 37548491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic stem cell transplant cytomegalovirus infection.
    Saleh AJ; Al Mohareb F; Al Rabiah F; Chaudhri N; Al Sharif F; Al Zahrani H; Mohamed SY; Patel M; Rasheed W; Nurgat Z; Bakr M; Ahmed S; Zaidi S; Nasser A; Ibrahim K; Al Abdely H; Aljurf M
    Hematol Oncol Stem Cell Ther; 2010; 3(3):116-20. PubMed ID: 20890068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients.
    Jorgenson MR; Descourouez JL; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
    Transpl Infect Dis; 2021 Aug; 23(4):e13693. PubMed ID: 34309158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of spontaneous cytomegalovirus clearance after low level reactivation using a pre-emptive treatment threshold of 4,000 IU/mL in allogeneic hematopoietic cell transplant recipients.
    Walling M; Seago K; Dillaman M; Yingling S; Wen S; Veltri L; Ross KG; Cumpston A
    J Infect Chemother; 2024 Dec; 30(12):1233-1236. PubMed ID: 38815653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients.
    Körholz KF; Füller MA; Hennies M; Holterhus M; Hagedorn S; Ahlmann M; Thorer H; Burkhardt B; Groll AH
    Paediatr Drugs; 2023 Mar; 25(2):225-232. PubMed ID: 36572834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance.
    Lindsay J; Othman J; Kerridge I; Fay K; Stevenson W; Arthur C; Chen SC; Kong DCM; Pergam SA; Liu C; Slavin MA; Greenwood M
    Transpl Infect Dis; 2021 Jun; 23(3):e13548. PubMed ID: 33342000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.
    Panagou E; Zakout G; Keshani J; Smith C; Irish D; Mackinnon S; Kottaridis P; Fielding A; Griffiths PD
    Transpl Infect Dis; 2016 Jun; 18(3):405-14. PubMed ID: 27061703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation.
    Ayala E; Greene J; Sandin R; Perkins J; Field T; Tate C; Fields KK; Goldstein S
    Bone Marrow Transplant; 2006 May; 37(9):851-6. PubMed ID: 16532016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CMV prevention strategies in allogeneic hematopoietic cell transplantation; the role of prophylaxis and pre-emptive monitoring in the era of letermovir.
    Yong MK; Slavin MA; Chemaly RF; Papanicolaou GA
    Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14171. PubMed ID: 37864299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters.
    Chan ST; Logan AC
    Blood Rev; 2017 May; 31(3):173-183. PubMed ID: 28173959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data.
    Pang I; Chen P; Trinh GV; Remberger M; Novitzky-Basso I; Gerbitz A; Kim DD; Kumar R; Lam W; Law AD; Lipton JH; Viswabandya A; Pasic I; Mattsson J; Michelis FV
    Eur J Haematol; 2024 Feb; 112(2):301-309. PubMed ID: 37830403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus Therapy: Role of Letermovir in Prophylaxis and Treatment in Transplant Recipients.
    Saullo JL; Miller RA
    Annu Rev Med; 2023 Jan; 74():89-105. PubMed ID: 36332639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
    Takenaka K; Eto T; Nagafuji K; Kamezaki K; Matsuo Y; Yoshimoto G; Harada N; Yoshida M; Henzan H; Takase K; Miyamoto T; Akashi K; Harada M; Teshima T;
    Int J Hematol; 2009 Mar; 89(2):231-237. PubMed ID: 19148587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.